Development and Evaluation of Dual-responsive Nano-herbosomes Co-loaded with <i>Piper betle</i> Extract for Targeted Anti-inflammatory Activity
Background: The purpose of the study was to address the significant challenges in treating novel inflammatory diseases in newborns, such as necrotizing enterocolitis, bronchopulmonary dysplasia, and neonatal sepsis. These conditions are difficult to manage due to their complex nature, limited pharmacological options, and the detrimental effects of existing anti-inflammatory therapies. Aim: To develop a dual-responsive nano-herb some system for targeted neonatal inflammation therapy. Method: It involved synthesizing this system through thin film hydration, co-loading it with curcumin and Piper betle extract-both known for potent anti-inflammatory capabilities. The formulations featured polymeric pH-sensitive Eudragit S100 and chitosan enzyme responsive coatings. Characterization confirmed nano-sized vesicles (~162 nm), high entrapment efficiency (>80%), and a stable zeta potential (?32.7 mV), validating successful drug encapsulation. In vitro simulations demonstrated sustained drug release at inflamed tissue conditions (pH 5.5) and evaluated anti-inflammatory activity via protein denaturation inhibition, RBC membrane stabilization, and cytokine signalling reduction. Results: Results indicated that the system exhibited marked anti-inflammatory activity, inhibiting protein denaturation by 89.4%, stabilizing RBC membranes by 84.6%, and significantly reducing cytokine signalling (TNF-?: 60%, IL-6: 58%, IL-1?: 52%). These effects were superior to free actives and standard diclofenac. Conclusion: It has been concluded that this nano-herbosomal system may be effectively employed as a targeted therapy for inflammation in neonate patients. Major Findings: Nano-herbosomes (~162 nm) showed >80% entrapment, sustained release, and strong anti-inflammatory activity, including protein denaturation inhibition (89.4%) and RBC membrane stabilization (84.6%).